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This section addresses a series of important topics which
impact the outcomes of people with CKD. Specifically CVD,
interpretation of tests for CVD, infections, vaccinations and
hospitalizations, medications, and patient safety are ad-
dressed. This section is designed to help the practitioner
appreciate the specific nuances related to testing and drug
administration in people with CKD and to alert all clinicians
to the fact that many common tests may not be as useful in
people with CKD to diagnose or evaluate therapies. It was
beyond the scope of the guideline and evidence review to
thoroughly evaluate all tests with respect to sensitivity and
specificity in different groups of people with CKD but future
research may consider this as a useful direction.
4.1 CKD and CVD
Population-based studies have demonstrated an increased risk
of death and cardiovascular mortality as GFR falls below 60
ml/min/1.73 m2 or when albumin is detected on urinalysis.
This is not explained by an increase in traditional risk factors.
There are CKD-specific risk factors associated with more
advanced CKD which drive the high rates of mortality and
morbidity even at young ages. People with CKD are more
likely to experience a cardiovascular event than to progress to
ESRD, have a worse prognosis with higher mortality after acute
myocardial infarction (MI), and have a higher risk of recurrent
MI, heart failure and sudden cardiac death. Management of
modifiable cardiovascular risk factors, such as improved BP
and diabetes control, also reduces CKD progression.
4.1.1: We recommend that all people with CKD be
considered at increased risk for cardiovascular
disease. (1A)
RATIONALE
This statement is worded in this way to reflect the strong and
independent associations between GFR and albuminuria
categories and risk of CVD in people with CKD and applies
to both adult and pediatric populations.
Evidence Base
Large cohort studies have demonstrated the strong and inde-
pendent associations between CVD (acute coronary syndrome
[ACS], stroke, heart failure and sudden cardiac death) and
CKD by category of eGFR, after adjusting for known CVD risk
factors, history of CVD events, and proteinuria. In those with
an eGFR of 45-59 ml/min/1.73 m2, risk is increased by 43%
and in those with eGFR below 15 ml/min/1.73 m2, risk is
increased by 343%.58 Although people with GFR category G5
(GFRo15 ml/min/1.73 m2) are at the highest risk of a CVD
event, there will be more events in people with GFR categories
G3a-G3b (GFR 30–59 ml/min/1.73 m2) because of the much
higher prevalence at these categories.420 These events occur at a
younger age in people with CKD suggesting that CKD
promotes CVD at an accelerated rate.421 The prognosis after
an acute event is related to level of GFR with a significant rise
in mortality when eGFR falls below 45 ml/min/1.73 m2.422–424
Albuminuria is associated with duration and severity of
hypertension; an adverse lipid profile with higher levels of
total cholesterol, triglycerides and lipoprotein(a) and low
HDL-C levels;425 and abnormalities of coagulation. The
presence of higher levels of proteinuria increases the risk of
mortality and MI independently of level of eGFR.426 Many
studies have demonstrated low levels of urinary albumin to
be associated with the increased risk of CVD in people with
diabetes independent of renal function; however population
studies of non-diabetic individuals have confirmed that even
small amounts of albuminuria are associated with increased
CVD risk. In the Third Copenhagen study, in people with
microalbuminuria, risk of coronary heart disease was
increased independently of age, sex, renal function, diabetes,
hypertension, and plasma lipids.427 The Chronic Kidney
Disease Prognosis Consortium demonstrated that in general
practice cohorts there was an increase in cardiovascular
mortality when ACR is higher than 30 mg/g (3 mg/mmol).4
Analysis of data from the Heart Outcomes Prevention
Evaluation (HOPE) study demonstrated that any degree of
albuminuria is a risk factor for cardiovascular events in
individuals with or without diabetes.428 The lack of a
threshold of albuminuria for cardiac risk was also confirmed
in the HUNT 2 Study429 and the Losartan Intervention For
Endpoint Reduction in Hypertension (LIFE) study in
patients with LVH.430 Albuminuria and low eGFR were
synergistic cardiovascular mortality risk factors in the
HUNT 2 study and using both ACR and eGFR improved
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cardiovascular risk stratification at all age levels, but
particularly in persons 70 years and over.429
In the MDRD Study cohort of patients with GFR
categories G3a-G4 (GFR 15–59 ml/min/1.73 m2), cystatin C
level was strongly associated with all-cause and cardiovas-
cular mortality particularly in the elderly.431 Analysis of data
from MESA and the Cardiovascular Health Study (CHS)
demonstrated that the worst prognosis of CVD, heart failure,
and progressive CKD was found in those subjects with CKD
diagnosed using the cystatin C-based equation.432
LVH is common with CKD, is known to reflect target
organ damage, and is associated with increased cardio-
vascular mortality in CKD.360 It is also important to consider
the role of CKD-specific risk factors particularly in patients
with more severe CKD (GFR o30 ml/min/1.73 m2) and
correct them where possible. Anemia has been thought to
have a particular role in the early development of CVD in
people with CKD. Although treatment of anemia is
associated with improved well-being and greater exercise
capacity, the results of several RCTs of anemia correction
have suggested that complete correction of anemia is not
advisable in people with lower GFR (o60 ml/min/1.73 m2).
A meta-analysis of 9 RCTs comparing different target Hb
levels suggests an increase in mortality and worse BP control
with the higher treatment targets, independent of the GFR
category.433,434 Those patients with LVH at baseline, a sign of
target organ damage and which was present in 47% of the
Cardiovascular Risk Reduction by Early Anemia Treatment
with Epoetin Beta Trial (CREATE) cohort, had significantly
worse cardiovascular outcomes when treated to the higher
targets.435
Abnormalities of mineral metabolism with low 1,25-
dihydroxyvitamin D and PTH were found to occur early in
CKD in the Study for the Evaluation of Early Kidney disease
[SEEK] study, however serum calcium and phosphate were
usually normal until eGFR fell below 40 ml/min/1.73 m2.367
An association between elevated serum phosphate and
cardiovascular mortality was demonstrated in a prospective
study of people with CKD and this was also thought to be
associated with low vitamin D levels.436
Pediatric Considerations
While the majority of data for, and evidence of, the high risk
of cardiovascular morbidity and mortality in the pediatric
renal population stems from the ESRD (dialysis and
transplant) populations,437–440 there is recognition that many
if not all of the factors responsible for such outcomes will
develop much earlier in this course of CKD. In fact, the
current American Heart Association’s guidelines for reduc-
tion of cardiovascular risk in pediatrics stratified the child
with CKD to the highest risk category.441
Based on data from the CKiD trial, Wilson et al.442
demonstrated extremely high prevalence rates for four
traditional cardiovascular risk factors (hypertension, dyslipi-
demia, abnormal glucose metabolism, and obesity) in a
subgroup of this cohort of 586 children with iohexol GFR
proven mild to moderate CKD. In this cross-sectional
analysis of 250 children who had data on all variables of
interest, median GFR of 45.2 ml/min/1.73 m2 (IQR 34.6-
58.2), the prevalence of hypertension was 46%, dyslipidemia
was 44%, abnormal glucose metabolism was present in 21%,
and obesity in 15%. Hypertriglyceridemia was common, seen
in 33%. In aggregate, only 26% of the cohort had no risk
factors present, 39% had at least one and 22% had two, 11%
had three and 2% had all four risk factors present. The
prevalence of all these factors remained elevated even when
the population was restricted to those defined as lean, BMI
o85th. In this group, the presence of 2 or 3 cardiovascular
risk factors was still seen in 20% and 2%, respectively. Within
the lean group 12% demonstrated abnormal glucose
metabolism. Finally, multivariate regression analysis of their
data demonstrated that glomerular disease as a cause of CKD
and the presence of nephrotic range proteinuria were
associated with much higher odds of having cardiovascular
risk factors, 1.96 (95% CI 1.04-3.72) and 2.04 (95% CI 0.94-
4.43), respectively.
It is also well-recognized that carotid intimal media
thickness and pulse wave velocity changes, as potential
surrogate measures for vascular damage in children, can be
increased in in children with CKD.443,444
For further detailed discussions of the pathophysiology
and complexity of CVD in the pediatric CKD population,
two recent review papers from Mitsnefes445 and
Shroff et al.446 are suggested. Both papers identify and
discuss the pathophysiology of both traditional and CKD-
specific cardiovascular risk factors as seen in this population.
4.1.2: We recommend that the level of care for ischemic
heart disease offered to people with CKD should
not be prejudiced by their CKD. (1A)
4.1.3: We suggest that adults with CKD at risk for
atherosclerotic events be offered treatment with
antiplatelet agents unless there is an increased
bleeding risk that needs to be balanced against the
possible cardiovascular benefits. (2B)
RATIONALE
These statements are worded in this way to reflect the
growing body of evidence that suggests that treatment of
traditional risk factors in CKD patients is of benefit, and that
attempts to modify or preclude usual investigations and
therapies are not necessary in CKD patients. Inasmuch as
CKD populations have been understudied, but likely
inadvertently included in larger population studies,
the rationale for risk factor modification is similar to that
in the general population. Modification of risk factors
includes:
1. Smoking cessation
2. Exercise
3. Weight reduction to optimal targets
4. Lipid modification recognizing that the risk reduction
associated with statin therapy in adults with CKD is
92 Kidney International Supplements (2013) 3, 91–111
chapte r 4
relatively constant across a broad range of baseline low-
density lipoprotein cholesterol (LDL-C) levels
5. Optimal diabetes control HbA1C o7% (53 mmol/mol)
6. Optimal BP control to o140/90 mm Hg or o130/80
mm Hg in those with CKD and depending on the degree
of proteinuria (see Recommendations 3.1.4 and 3.1.5)
7. Aspirin is indicated for secondary prevention but not
primary prevention
8. Correction of anemia to individualized targets (see
KDIGO Clinical Practice Guideline for Anemia in CKD11)
Evidence Base
The maintenance of cardiovascular health ultimately
impacts ‘kidney health’ given the links between cardiac
function, renal perfusion, atherosclerosis, and glomerulo-
sclerois. The details of this complex biology are beyond
the scope of these guidelines, but can be found in key
references below.
There is evidence in the general population that smoking
cessation is associated with a reduction in cardiovascular risk.
In CKD there is evidence that smoking is associated with
progression of renal disease, though no specific data exist that
support cessation of smoking and delay of progression.447
People with CKD have reduced levels of muscle strength
and aerobic activity. In those not on dialysis, exercise training
is shown to improve functional capacity and BP.448
Weight loss in obese CKD patients can reduce rate of
decline, proteinuria, and BP.354
The Study of Heart and Renal Protection (SHARP)449 is
the largest RCT in people with CKD to date. The results
demonstrate that a lipid-lowering strategy which included
fixed dose simvastatin and ezetimibe resulted in a 17%
reduction in atherosclerotic events, as compared to placebo.
The cohort enrolled included those with eGFR under 60 ml/
min/1.73 m2, age greater than 40 years, and was an
international study including more than 9000 subjects from
around the globe. The lipid-lowering strategy was effective
and safe. Lipid targets have not been established specifically
for people with CKD. Treatment strategies should be
implemented in accordance with current recommendations
for high-risk populations.
At the time of this writing, the KDIGO Clinical Practice
Guideline for Lipid Management in Chronic Kidney Disease
was under preparation for public review. In brief, the key
aspects of the draft recommendations include treating those
at high risk for atherosclerotic disease with lipid-lowering
therapies, regardless of LDL levels, in those 50 years of age
and above. Since this Guideline has not yet been finalized,
interested readers should refer to the final document when it
is formally released in 2013.
The benefits of aspirin in people with CKD and
hypertension was demonstrated in a post hoc analysis of the
Hypertension Optimal Treatment (HOT) trial.450 Jardine
et al. reported that among every 1000 persons with eGFR
o45 ml/min/1.73 m2 treated for 3.8 years, 76 major
cardiovascular events and 54 all-cause deaths will be
prevented while 27 excess major bleeds will occur. They
concluded that an increased risk of major bleeding appears to
be outweighed by the substantial benefits. Clopidogrel is used
as an alternative to aspirin but CKD has been shown to be
associated with an increase in platelet reactivity and there is
resistance to clopidogrel in people with CKD, diabetes, and
CVD.451 The Clopidogrel for Reduction of Events During
Observation (CREDO) trial concluded that clopidogrel in
mild or moderate CKD may not have the same beneficial
effect as it does in people without CKD. Subjects with normal
renal function who received 1 year of clopidogrel had a
marked reduction in death, MI, or stroke compared with
those who received placebo (10.4% versus 4.4%, P o0.001),
whereas those with mild and moderate CKD did not have a
significant difference in outcomes with clopidogrel therapy
versus placebo (mild: 12.8% versus 10.3%, P ¼ 0.30;
moderate: 13.1% versus 17.8%, P ¼ 0.24). Clopidogrel use
was associated with an increased RR of major or minor
bleeding, but this increased risk was not different based on
renal function.452
International Relevance
Although it is clear and mentioned in many guidelines that
CKD is associated with an increase in CVD risk, it is not
included in many assessment tools and there is a deficiency in
ethnicity and regional specific tools.
The assessment tool from US Third Report of the National
Cholesterol Education Program (NCEP III) does not include
CKD. The Fourth Joint Task Force of the European Society of
Cardiology suggest that both an eGFR of less than 60 ml/
min/1.73 m2 and albuminuria increase risk but do not
quantify the risk or include CKD in their Systematic
COronary Risk Evaluation (SCORE) assessment tool.453 In
the UK, the QRISKs2 online tool includes CKD as ‘yes’ or
‘no’ and therefore does not allow for level of eGFR or
proteinuria.454 The Joint British Societies Guidelines regards
proteinuria as a sign of target organ damage, which conveys a
risk of at least 20% in 10 years.455
A study of cardiovascular risk estimation in Chinese adults
in the USA–People’s Republic of China Collaborative Study of
Cardiovascular and Cardiopulmonary Epidemiology (USA-
PRC Study) did not include CKD as a risk factor at all.456 It is
also important to remember that in this population stroke
was the predominant CVD. A review of 25 risk assessment
tools identified only 2 derived from an Asian population.457
However, links between GFR categories and CVD events are
evident in the Asian population, for example in the Japanese
Gonryo study.458 A prospective study in a general Japanese
population demonstrated links between lower GFR, high
creatinine levels, and proteinuria with cardiovascular mor-
tality particularly stroke.459 In Chinese patients who were at
least 50 years old and either had existing CVD or were at high
risk, 34% had an eGFRo60 ml/min/1.73 m2 and eGFRo45
ml/min/1.73 m2 was found to be an independent predictor of
all-cause and cardiovascular death.460 In a population-based
study of 2353 people aged over 40 years in Beijing, an eGFR
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o90 ml/min/1.73 m2 was associated with increased CVD
risk, and for each CKD category stroke was more prevalent
than MI.461
In India the increasing prevalence of type 2 diabetes is
driving an increase in CKD and both are associated with
increased cardiovascular risk. In CKD patients attending one
clinic in North India, 28% had diabetes, 27% were overweight,
and 92% had hypertension. Metabolic syndrome as defined by
the International Diabetes Federation (IDF) 2007 guidelines
was present in 39% and more frequent in women.462
Implications for Clinical Practice and Public Policy
A full CVD risk assessment in a person with CKD should
include an estimate of GFR and a quantitative assessment of
albuminuria. Cystatin C may be helpful at risk stratifying
those at intermediate risk.
The key aspect of these recommendations is to ensure that
people with CKD are not deprived of treatment strategies
known to be effective in general populations.
Areas of Controversy, Confusion, or Non-consensus
Many of the traditional cardiovascular risk assessment tools
do not adjust for the presence of early CKD. Any tool should
also adjust for level of eGFR because of increasing risk
associated with lower levels of kidney function. The
Framingham risk equation underestimates true events in a
CKD population, but no validated different tools exist at
present which better quantify cardiovascular or mortality risk
in CKD populations.
Proteinuria is considered to be a sign of target organ
damage and thus associated with high cardiovascular risk.
However, assessment of risk should also include the presence
of albuminuria. Few studies exist which demonstrate that
targeting lowering of proteinuria results in reduced cardio-
vascular risk, though a number of studies which have
targeted interruption of the RAAS (and in which lowering
of urine protein has also been shown) have demonstrated a
benefit.
An appropriate risk assessment tool should be available to
assess risk in people with CKD. Addition of the presence of
CKD to conventional risk factors in the Reykjavik population
increased discrimination but did not increase risk to the same
degree as smoking or diabetes.463 In the Framingham Heart
Study, GFR category 3b (GFR 30–44 ml/min/1.73 m2) was
associated with CVD but not equivalent to previous CVD.464
Lifestyle modification has not been studied in large trials
in people with CKD but smoking cessation, achievement of
optimum weight, regular exercise, and salt restriction should
be seen as reasonable aims.
Pediatric Considerations
It is presently unclear whether children with CKD and
elevated lipid levels will benefit from lipid-lowering strategies
with no prospective trials ongoing in this area. It is hoped
that data from both CKiD55 and the 4C trials78 may be able to
address these shortcomings.
However, given that these children demonstrably have
elevated risk of cardiovascular and atherosclerotic disease (see
Recommendation 4.1.1), that there are data supporting the
use of a number of statins in the pediatric population,465 and
that the adult evidence for benefit of statins in a subset of the
SHARP trial449 with a GFR o60 ml/min/1.73 m2 exist, it
would seem reasonable to consider the use of such drugs in
children with CKD and elevated lipids.
Recommendations from 2006441 for use of dietary
modifications, followed by statins in children older than 8
years of age with persistent elevation in LDL-C levels, have
been endorsed by the American Academy of Pediatrics.
However, at the time of publication of these guidelines, the
KDIGO Dyslipidemia Work Group has suggested that statin
therapy may not be appropriate.
Age- and renal function-adjusted doses of such drugs
should be carefully considered prior to any therapy being
initiated (see Recommendation 4.4.1).
Regarding diabetes control, treatment in keeping with
national and international diabetes recommendations is
prudent. Note is made that there are specific caveats with
respect to drugs and side effects that are important (see
Recommendations 3.1.15-3.1.18).
There is no literature in the area of antiplatelet agents in
atherosclerotic disease in the subset of children with CKD
and the suggestion to offer antiplatelet agents does not apply
to pediatric practice.
4.1.4: We suggest that the level of care for heart failure
offered to people with CKD should be the same as
is offered to those without CKD. (2A)
4.1.5: In people with CKD and heart failure, any
escalation in therapy and/or clinical deterioration
should prompt monitoring of eGFR and serum
potassium concentration. (Not Graded)
RATIONALE
This statement is worded this way to make clinicians aware
that people with CKD and heart failure should receive at least
equal benefit from heart failure therapy as those without
CKD, but that heart failure therapies (in particular increase
of RAAS blockade and diuretic therapy) may lead to
significant changes in GFR and serum potassium concentra-
tions. This does not imply that such therapy should be
avoided but only that clinicians are cognizant of this
possibility, monitor it, and understand it in the context of
individual risks and benefits.
Heart failure is a complex clinical syndrome which can be
caused by any structural or functional cardiac disorder that
impairs the pump function of the heart and has a high
mortality. Within the general population, the commonest
causes of heart failure are ischemic heart disease causing left
ventricular systolic dysfunction, and hypertensive heart
disease with left ventricular hypertrophy and diastolic
dysfunction. Thus people with CKD are at increased risk of
both. Evidence-based medication for heart failure impacts on
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GFR and prescribers need to be alert to this. Changes in GFR
are often transient and the downward trajectory GFR is not
sustained if all other aspects of care and clinical status are
stable. Monitoring and close follow-up are required.
Evidence Base
In an outpatient setting, normal GFR is unusual in heart
failure. A study from the Alberta Heart Function Clinic found
that in people with an ejection fraction of r35%, GFR
categories G3a and G3b (GFR 30–59 ml/min/1.73 m2) were
present in 40% and 16% of people were GFR categories G4 or
G5 (GFRo30 ml/min/1.73 m2).466 This study demonstrated a
1% increase in mortality associated with each 1 ml/min fall in
CrCl demonstrating the clear link between kidney function
and outcome for people with CKD and heart failure. Meta-
analysis of 16 studies and over 80,000 people with heart failure
by Smith et al. showed that renal impairment was present in
63% and was associated with increased mortality across the
range of kidney function, with an adjusted HR of 1.56 (95% CI
1.53-1.60).467 In the Candesartan in Heart Failure-Assessment
of Reduction in Mortality and Morbidity (CHARM) Program
with candesartan in heart failure, 36% of subjects had eGFR
o60 ml/min/1.73 m2 which was associated with increased
mortality and hospital admission regardless of ejection
fraction.468 The Digitalis Intervention Group (DIG) identified
a GFR of 50 ml/min as a risk threshold for increased mortality
risk in heart failure.469 Smith et al. demonstrated that 1-year
mortality after admission for heart failure was 29% in people
with normal kidney function but 52% in those with moderate
to severe renal impairment.470 Anand et al. also demonstrated
an independent association between the presence of positive
reagent strip proteinuria present in 8% of subjects and
increased mortality in heart failure.471
In the Alberta Provincial Project for Outcome Assessment
in Coronary Heart Disease (APPROACH) study of people
with heart failure related to coronary artery disease (CAD),
39% had CrCl o60 ml/min (o1 ml/s). This study also
demonstrated that the level of kidney function was a better
indicator of poor outcome than cardiac anatomy.472 In
people admitted to hospital with heart failure, increasing SCr
concentration is associated with a longer hospital stay and
worse outcome.473
LVH is present in 40% of people with CKD,474
progressively increasing as kidney function declines.475
Ha et al. demonstrated LVH in 87% of people with
predialysis CKD.476 Parfrey et al. in a study of 432 people
who were predialysis, found that only 16% had a normal
echocardiogram while 41% had concentric LVH, 16% systolic
dysfunction, and 28% left ventricular dilatation.477 LVH is
related to increased work load caused by arterial stiffness and
hypertension, and at lower levels of GFR, volume overload.
Alterations in electrolyte balance, anemia, bone metabolism,
uremia, oxidative stress, inflammation, and other inflamma-
tory mechanisms all play a role.478
In the majority of people with CKD, the myocardium
develops concentric hypertrophy476 with interstitial fibrosis
and CKD-associated cardiomyopathy, leading to left ventri-
cular stiffness.474 This results in diastolic heart failure; people
with CKD have higher mortality from diastolic heart failure
than systolic heart failure.479 Diastolic heart failure is more
common in people with CKD who are older females with
hypertension and/or diabetes.480
Left ventricular hypertrophy is particularly associated with
anemia and a fall in Hb to less than 12.8 g/dl (128 g/l) is
associated with left ventricular growth in people with early
CKD.481 Lower Hb levels are associated with increased risk of
death and hospitalization in heart failure.482 Other cardio-
vascular conditions, for example MI and atrial fibrillation, are
more common in CKD and may exacerbate heart failure.
It is important to note that in a study of an older
population (age 464 years), heart failure was an indepen-
dent predictor of rapid kidney function decline.483
Standard therapy for the management of systolic heart
failure includes an ACE-I or ARB and a beta-blocker licensed
for heart failure such as bisoprolol or carvedilol. Meta-
analysis of 25 trials of RAAS blockade (ACE-I or ARB) in
people with CKD or proteinuria, demonstrated a reduction
in the risk for heart failure and reduction in cardiovascular
outcomes.484 Subgroup analysis from the Valsartan Heart
Failure Trial (Val-HeFT) demonstrated the beneficial effect of
valsartan in people with CKD and that valsartan reduced the
eGFR by the same amount in people with and without
CKD.471 Candesartan was also clinically effective in the
CHARM study regardless of underlying kidney function468
while irbesartan was associated with a 23% reduction in
hospital admissions related to heart failure in people with
nephropathy due to type 2 diabetes.485 Analysis of data on
bisoprolol from the Cardiac Insufficiency Bisoprolol Study II
(CIBIS II)486 identified 32% of subjects with eGFR o60 ml/
min/1.73 m2. These subjects were more likely to die or be
admitted to hospital than those with eGFRZ60 ml/min/1.73
m2. However, they showed a similar benefit from bisoprolol
treatment. A post hoc analysis of data on carvedilol from the
Carvedilol Post-Infarct Survival Control in Left Ventricular
Dysfunction (CAPRICORN) and Carvedilol Prospective
Randomized Cumulative Survival (COPERNICUS) trials
identified 60.8% of participants with eGFR o60 ml/min/
1.73 m2.487 Carvedilol was well tolerated by subjects with
CKD, and decreased all-cause, cardiovascular, and heart
failure mortality. However, doubts were raised over the
benefits when eGFR o45 ml/min/1.73 m2.
Aldosterone antagonists are included in standard heart
failure management, usually in addition to an ACE-I or ARB,
leading to concerns relating to risk of hyperkalemia,
particularly in people with lower GFRs. In a study of
spironolactone therapy in severe heart failure, Pitt et al.488
included subjects with SCr concentrations up to 2.5 mg/dl
(221 mmol/l). There was a 30% reduction in mortality with
spironolactone and the incidence of hyperkalemia was low.
However, a review of real-world practice demonstrated a
significant increase in hyperkalemia with the combination of
RAAS blockade and an aldosterone antagonist, highlighting
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the need for close monitoring with the introduction of
combination therapy.489
In the APPROACH study on the specialist management
of heart failure, subjects with CAD and CKD, despite
being at high risk, were less likely to be taking ACE-Is,
beta-blockers, statin, and aspirin. This study demonstrated
that those subjects taking beta blockers had lower mortality,
however ACE-Is were only of benefit when eGFR was
460 ml/min/1.73 m2.472
International Relevance
The treatment of heart failure is similar around the globe. The
ability to closely monitor kidney function or to offer
conventional therapies may differ, however. Irrespective, this
statement should hold true internationally. The National Heart
Care Project of community subjects admitted to hospital with
heart failure studied the differences between people of black
and white ethnic groups. People with worse renal function
were more likely to be black, older and female, and black
people had a greater prevalence of hypertension and diabetes
but less ischemic heart disease. Black people had a lower risk of
mortality at every level of creatinine, for every 0.5 mg/dl
(44.2 mmol/l) increase in creatinine, 1-year death risk increased
10% in black people and 15% in white people.470
Implications for Clinical Practice and Public Policy
Cardiorenal syndrome, an impairment of kidney function in
the presence of heart disease, is a marker of worse prognosis.
In addition to GFR, the presence and severity of albuminuria
and anemia aid in prognostication and management.490
Where the link between LVH and heart failure in CKD is
so strong and the outcome poor for people with LVH, efforts
should be made to optimize care particularly BP. There is a
lack of robust evidence for the optimal medical management
of heart failure specifically in people with CKD; however, the
prevalence of people with early CKD is so high in heart
failure trials that we can apply standard treatment to these
people. For those people with eGFR o45 ml/min/1.73 m2,
the situation is less clear.487
Areas of Controversy, Confusion, or Non-consensus
There are difficulties in making the diagnosis of heart failure
in people with CKD, especially diastolic heart failure.
Biomarkers such as B-type natriuretic peptide (BNP) may
be abnormally elevated in CKD, but may or may not
be as responsive to treatment or diagnostically accurate in
people with CKD (see Chapter 4.2). There is little evidence
to guide the management of left ventricular systolic
dysfunction in people with CKD and evidence for the
management of diastolic heart failure is generally lacking.
However, there is evidence that medications to improve the
outcome of people with heart failure are underused in people
with CKD.
Appropriate management of the metabolic complications
of kidney disease which can exacerbate heart failure needs to
be clarified. Clinical studies are required on the role of
device therapy in people with CKD (e.g., pacemakers,
defibrillators, etc.).
4.2 CAVEATS WHEN INTERPRETING TESTS FOR CVD IN
PEOPLE WITH CKD
BNP/N-terminal-proBNP (NT-proBNP)
As GFR diminishes, the prevalence and severity of cardio-
vascular abnormalities increase and are accepted as major
causes of morbidity and mortality in people with CKD. The
presence of congestive heart failure (CHF) in people with
CKD conveys a worse prognosis than either condition alone.
Therefore, early diagnosis and aggressive management of
CHF are both highly desirable. A number of cardiac
biomarkers (i.e., BNPs and cardiac troponins) appear to
have both increasing clinical importance and increasing
facility for detection and stratification of CHF. The stimulus
for secretion of these biomarkers is the hemodynamic load
(i.e., myocardial stretch) and their secretion is associated with
the severity of CHF and the degree of left ventricular
dysfunction. They are thus useful markers for diagnosis,
management, and prognosis in people with normal renal
function. However, when the eGFR is less than 60 ml/min/
1.73 m2, the accuracy of plasma BNP and NT-proBNP levels
for detection and stratification of CHF becomes unreliable
and the degree of responsiveness to treatment is not known.
4.2.1: In people with GFR o60 ml/min/1.73 m2 (GFR cate-
gories G3a-G5), we recommend that serum concentra-
tions of BNP/NT-proBNP be interpreted with caution
and in relation to GFR with respect to diagnosis of
heart failure and assessment of volume status. (1B)
RATIONALE
This statement is intended to remind clinicians that although
the prevalence of fluid overload and heart failure increases
with lower GFR categories, BNP becomes less reliable as a
predictor of fluid overload and heart failure at lower GFRs.
While it is associated with worse outcomes, cutoff values
indicative of heart failure in general populations may or may
not be appropriate and changes in values with treatment may
or may not have the same meaning.
Evidence Base
Natriuretic peptides belong to a family of circulatory peptide
hormones from either myocardial cell origin (atrial natriure-
tic peptide [ANP] and BNP) or endothelial cell origin
(C-type).491,492 They play an important role in regulating BP
and body fluid volume by their natriuretic and diuretic
actions, arterial dilatation, and inhibition of the RAAS.493
Natriuretic peptides for the diagnosis of CHF have been a
diagnostic breakthrough in cardiology where determination
of their concentration in serum can help identify patients
with left ventricular systolic dysfunction.494,495
Concentrations of natriuretic peptides increase in
people with CHF and other CVDs as a consequence of
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pressure and volume overload.496,497 Among people with
progressive LVH, concentrations of NT-proBNP are typically
elevated in proportion to the degree of left ventricular mass
increase.
Overall, BNP levels provide a better index of left
ventricular mass and load than do ANP levels and BNP has
emerged as a superior biomarker to ANP for clinical
applications involving CHF and left ventricular dysfunc-
tion.491,498 NT-proBNP may have analytical advantages over
BNP because of greater stability due to a longer half-life.
The cause of an elevated BNP level is multifactorial in
origin and may reflect cardiac dysfunction, and/or changes in
renal function.499 Since renal dysfunction intrinsically was
shown to affect BNP levels in some studies, the diagnostic
value of BNP levels in the presence of CKD has been
questioned.500,501
Earlier research hypothesized that measurement of
natriuretic peptides could be of use in monitoring
excess fluid volume and dry weight in people requiring
dialysis,502,503 but this remains unproven and the significance
of plasma natriuretic peptides and their clinical role in
dialysis remains unclear.491
Although several studies revealed higher BNP levels as
GFR declined, outcomes of other studies suggest that the
relationship between renal function and BNP levels may be
most strongly dependent on cardiac and volume-related
factors.504–506 To test this hypothesis, Tagore et al. studied
BNP levels in a cohort of 143 clinically euvolemic subjects
with CKD in whom absence of heart disease was clinically
validated and found that plasma BNP levels were indepen-
dent of GFR.504 Suresh and Farrington507 studied people on
dialysis and concluded that BNP levels were predictive of
presence of left ventricular dysfunction, cardiac events, and
survival in the presence of ESRD, suggesting that BNP levels
may be informative across the full range of renal function and
even in its absence. As previously established by several
studies, the level of NT-proBNP is a strong prognostic
marker in both the general population508 and in various
disease states, e.g., acute and CHF,509,510 coronary heart
disease,511,512 and hypertension.513
International Relevance
The issue of how to differentially interpret BNP in the
presence or absence of CHF and within the context of
declining renal function has received considerable
attention but remains incompletely resolved from a clinical
perspective. Changes in either renal or cardiac function could
potentially impact levels of natriuretic peptides and incom-
plete knowledge of an individual’s clinical status relative
to the degree of cardiac pathology or renal dysfunction
could confound interpretation of BNP levels. Given the cost
of biomarkers assays and the uncertainties related to
interpretation of serum levels of BNP/NT-proBNP in people
with CKD, competing priorities for health-care resource may
dictate reliance on clinical evaluation and local practices
of care in some areas of the world. Until better data are
available, clinicians are asked to use this laboratory
measurement with caution as a diagnostic test for heart
failure in those with CKD.
Implications for Clinical Practice and Public Policy
Since people with ESRD with elevated levels of BNP have a
higher RR of death, this biomarker could be used as an
individual risk marker with the aim of identifying those at
high risk. Clinical correlation is of utmost importance to
ensure accurate diagnosis and appropriate therapy.
Studies to understand the variability of BNP by categories
of eGFR and urine ACR, within and between individuals over
time, and the response to therapy should be undertaken so as
to better inform clinicians.
Areas of Controversy, Confusion, or Non-consensus
The relationship between renal function and BNP, the role of
natriuretic peptides as markers of fluid overload and as
predictors of mortality, and the utility of serial monitoring of
BNP/NT-proBNP levels in people with CKD, and respon-
siveness to therapy remains unknown.
Clarification of issues and key points
Natriuretic peptides may be surrogate markers for prediction
of mortality in people with CKD reflecting the association
of mortality with left ventricular dysfunction and LVH.
Before routine measurements of these biomarkers are
recommended, their utility in guiding or changing clinical
practice should be assessed.
Pediatric Considerations
There is robust literature in both children and neonates
regarding both the normative values of BNP514 and its value
in predicting outcomes of pediatric heart failure.515 To date
no studies in children specifically address the issue of reduced
GFR in this population. However, application of similar
principles would likely apply.
Troponins
In recent years newer markers of myocardial injury have been
introduced into clinical practice.516,517 Among these, cardiac
troponins have proven to be specific markers of myocardial
damage.518,519 Cardiac troponins have been considered the
gold standard biochemical test for diagnosis of myocardial
damage because they have nearly absolute myocardial tissue
specificity, as well as high sensitivity, thereby reflecting even
microscopic zones of myocardial necrosis.517,520 Further-
more, increasing evidence indicates that abnormal troponin
measurements identify a subgroup of patients who have an
increased risk of major cardiac events519,521–525 and that
measurement of cardiac troponin T (cTnT) prior to
commencing renal replacement is a significant independent
predictor of survival.526 However, these markers are renally
excreted and are often found to be elevated in people with
CKD irrespective of specific symptomatology. Thus, there is
uncertainty as to the clinical importance of their different
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magnitudes of elevation in CKD. There are no data on
‘expected’ values of these markers in the context of CKD, or
at different categories of GFR and albuminuria.
4.2.2: In people with GFR o60 ml/min/1.73 m2 (GFR
categories G3a-G5), we recommend that serum
concentrations of troponin be interpreted with
caution with respect to diagnosis of acute coronary
syndrome. (1B)
RATIONALE
This statement is intended to remind clinicians that isolated
elevated serum concentrations of troponin (in the absence of
symptoms or electrocardiographic changes) may not necessa-
rily portend a diagnosis of ACS at lower GFR categories. While
there are data linking troponin elevations with poor outcomes,
the specific implications for an individual in clinical practice
are not clear. Hence, this statement simply cautions the
clinician with respect to interpretation but does not suggest
that the laboratory values are not of significance. In a patient
with clinical symptoms suggestive for ischemic heart disease,
an elevated cardiac troponin I (cTnI) is suggestive for ACS.
Evidence Base
cTnT and cTnI are low-molecular-weight proteins that form
part of the troponin complex and are integral components of
the myofibrillar contractile apparatus of the heart.527 Loss of
integrity of cardiac myocyte membranes causes release of
cardiac troponins into the circulation, which can be detected
by highly sensitive assays developed for cTnT and cTnI to
diagnose ACS.521 A potent stimulus for the release or
production of natriuretic peptides is mechanical stretch-
ing,528 whereas plasma cTnT specifically and sensitively
reflects myocardial injury and is considered to be an index
of irreversible myocardial change.521 In addition, cTnT levels
can predict multi-vessel CAD in people requiring dialysis.529
However, the significance of screening people with CKD for
CAD using these cardiac biomarkers is questionable530 since
increases in serum cardiac troponin concentration can occur
in the absence of an ACS.531
Most studies517,532–545 have focused on people with ESRD
where increases in serum cTnT concentrations have been
observed in 20%–90% of subjects540 but generally much
lower when cTnI was measured. Information about cardiac
troponins and their relationship with comorbidity is sparse
in people with CKD who are not receiving dialysis
treatment.526,527,546,547 Increased cardiac troponin concentra-
tions may occur early in CKD, including GFR categories
30-59 ml/min/1.73 m2, and more commonly as CKD advances.
Powerful prognostic data emerging from the dialysis
population demonstrate that increased concentrations of
cardiac troponins reflect either subclinical myocardial
damage caused by silent ischemia or myocardial remodeling
in the development of LVH.539,542
Increased levels of cTnT measured with the highly
sensitive assay, well below the detection range of standard
assays, have been shown to be associated with cardiac
structural abnormalities including LVH (both left ventricular
wall thickening and dilation) and left ventricular systolic
dysfunction,548 and to have a graded association with all-
cause and CVD mortality independent of traditional risk
factors, renal function, and levels of other biomarkers such as
high sensitivity CRP and NT-proBNP.
These findings suggest that chronic elevation of troponin
levels may be mediated to a greater extent by indices of heart
failure (such as higher left ventricular mass, left ventricular
dysfunction, or increased NT-proBNP levels) than indices of
atherosclerosis or ischemia.548
International Relevance
The costs of these tests, the differing sensitivity of the assays
available, the paucity of data in people with CKD, and the
poor correlation of serum troponin levels with ACS in people
with CKD should be weighed against competing local health-
care priorities and resource before their introduction into
routine clinical practice. Emphasis should be placed on the
clinical context and local standard practices of care.
Implications for Clinical Practice and Public Policy
Troponin elevation may result from repeated episodes of
clinically silent MI,522,549 although CAD frequently underlies
troponin elevation and increased cTnT is also frequently
encountered in patients at low risk for CAD. Troponin
elevations are as frequent in subjects without CAD as in those
with known CAD517,550–552 and in people with CKD, serial
increasing cTn levels may be of greater utility for diagnosis of
ACS. In the context of symptoms and signs of ACS,
elevations of troponins should not be ignored nor incorrectly
attributed to simply ‘CKD.’ Thus the importance of ordering
the test for specific indications for those with CKD should be
emphasized.
Areas of Controversy, Confusion, or Non-consensus
Information about cardiac troponins and their relationship
with comorbidity is sparse in people with CKD who are not
receiving dialysis treatment. Although elevated values for
TnT are common in people with low GFR in the absence of
ACS or CHF, the prevelance of elevated TnI in the absence of
ACS or CHF in people with low GFR may be only 0.4-6%
depending on the cutoff value chosen.532
Clarification of Issues and Key Points
As pointed out by Roberts et al.,553 although management
strategies in people without CKD based on these biomarkers
are quite clear, in people with CKD it is not the case despite
the strong data on the prognostic implications. These
biochemical markers can only be useful if they are interpreted
in the context of the clinical history and examination with
consideration given as to what management is appropriate
for each individual, and if a cardiovascular therapy that is
effective in this population is identified or developed.553 The
importance of understanding and contextualizing elevations
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in troponin values in CKD populations cannot be overstated:
under-treatment in symptomatic individuals should be avoided,
and better understanding of treatment strategies in those
asymptomatic individuals is the focus of ongoing study.
Pediatric Considerations
While normative values exist for troponin in children,554 its
utility as a general screening marker for myocardial ischemia
in pediatrics has recently been called into question,555 and no
data exist relating reduced renal function and troponin levels
in children.
Non-invasive testing
Most studies of cardiac evaluation in people with CKD have
involved candidates for kidney transplantation in order to
identify existing cardiac conditions amenable to risk
modification and to exclude people with short expected
survival due to cardiac morbidity. Among the tests for
cardiovascular assessment, coronary angiography is consid-
ered invasive, expensive, and associated with risks such as
contrast-induced nephropathy and cholesterol embolism.
When trying to detect CAD or predict future cardiovascular
events in people with CKD, nuclear imaging modalities using
thallium tracers have shown conflicting results, especially in
the context of small vessel disease. Clinicians should be aware
of the limitations of radionuclear testing as a screening tool for
significant CAD given the limitations of the test. Exercise-
dependent techniques are limited by poor exercise tolerance of
many subjects and people with CKD frequently have cardiac
evaluation performed with pharmacological agents.556,557
4.2.3: We recommend that people with CKD presenting with
chest pain should be investigated for underlying
cardiac disease and other disorders according to the
same local practice for people without CKD (and sub-
sequent treatment should be initiated similarly). (1B)
4.2.4: We suggest that clinicians are familiar with the
limitations of non-invasive cardiac tests (e.g., exercise
electrocardiography [ECG], nuclear imaging, echo-
cardiography, etc.) in adults with CKD and interpret
the results accordingly. (2B)
RATIONALE
These statements are worded in this way firstly because
although people with CKD are at increased risk from
cardiovascular events, observational study has shown that
they are frequently discriminated against in terms of
investigation and management of such events. Secondly,
non-invasive cardiac tests have known additional limitations
in people with CKD and such limitations and their
consequences need to be clearly understood by health
professionals caring for people with CKD.
Evidence Base
Noninvasive stress testing appears to be the most common
first approach to cardiac evaluation of asymptomatic
patients, prompted by diabetes, age and risk-factor burden.
These tests include myocardial perfusion studies, stress
echocardiography, and most recently, cardiac computed
tomographic angiography. However, people with CKD are
underrepresented in studies evaluating the diagnostic sensi-
tivities and specificities of noninvasive tests. Exercise ECG is
limited by lack of specificity of the ST-segment response and
by inability of many people with CKD to exercise to a
diagnostic workload.
These tests have imperfect sensitivity and specificity in
people with CKD or, in the case of tomographic angiography,
evaluation in this population is as yet unpublished.556 CAD
has been detected in a high proportion of people
on long–term dialysis therapy. Studies describing asso-
ciations of angiographic coronary stenosis with subsequent
clinical events in people with ESRD, including those under-
going transplant evaluations, have reached inconsistent
conclusions.558–562
Abnormalities on myocardial perfusion studies correlate
well with the presence of CAD in the general population,
with mean weighted sensitivity of 88% and mean weighted
specificity of 74%.563 The performance of myocardial
perfusion studies in identifying CAD in people with CKD
is more variable, with reported sensitivities and specificities
in people with ESRD ranging from 37% to 90% and 40% to
90%, respectively.564–567 Nonetheless, results from myocardial
perfusion studies have prognostic value for cardiac events
and mortality.568,569 In a meta-analysis of 12 studies
involving thallium-201 scintigraphy and dobutamine stress
echocardiography, people with ESRD with inducible ischemia
had approximately 6 times the risk of MI and 4 times the risk
of cardiac death as those without inducible defects.570
Moreover, subjects with fixed defects also had nearly 5 times
the risk of cardiac death.
The prognostic value of myocardial perfusion studies has
been shown with other perfusion tracers. For example, in a
study of 126 people with ESRD who underwent technetium-
99m myocardial perfusion studies as part of their pre-
transplant assessment, the presence of a reversible defect was
associated with 3 times the risk of post-transplant cardiac
events (HR 3.1; 95% CI 1.1-18.2) and nearly twice the risk of
death (HR 1.92; 95% CI 1.1-4.4) compared with normal test
results.571
De Lima et al.572 prospectively studied 126 renal transplant
candidates clinically classified as moderate (age450 years) or
high (diabetes, extra cardiac vascular disease, or known CAD)
coronary risk with myocardial perfusion studies, dobutamine
stress echocardiography, and coronary angiography. Significant
CAD, defined as greater than 70% stenosis in 1 or more major
epicardial artery on angiography was found in 42% of the
sample. After a median follow-up of 46 months, clinical risk
stratification and coronary angiography predicted major
cardiac events, but myocardial perfusion studies and dobuta-
mine stress echocardiography did not.
Newer imaging techniques are under current evaluation
but a review here is beyond the scope of this guideline; these
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techniques include: stress myocardial perfusion single
photon emission computed tomography (SPECT);557,573–576
18F-BMS, a novel fluorine-based myocardial per-
fusion tracer;557,577 and gated imaging using radio-labelled
ammonia (13NH3).
International Relevance
People with CKD who are being investigated prior to
transplantation should be assessed according to the national
and international cardiology guidelines and taking into
account local practice and availability of resource.
Implications for Clinical Practice and Public Policy
There is still a need for a safe, noninvasive, diagnostic
modality that will allow stratification of cardiovascular risk
among people with CKD. With the development of new
imaging markers, it becomes difficult for clinicians to choose
the imaging tests that can best aid clinical decisions for a
given patient. Imaging methods should provide accuracy and
precision at acceptable cost. Until advanced imaging
techniques (e.g., cardiac MRI, positron emission tomogra-
phy, cardiac computed tomography) are standardized,
clinicians should rely on the most reliable and familiar
techniques in their environment.578
Areas of Controversy, Confusion, or Non-consensus
Clinical and cost-effectiveness could be improved; cardiac
evaluation in people with CKD should be based on data from
clinical trials.
Clarification of Issues and Key Points
If cardiac evaluation is at present predominantly used for
risk stratification and prognosis, in the future it may guide
optimal therapy and monitor clinical progress.557
4.3 CKD AND PERIPHERAL ARTERIAL DISEASE
There is a strong link between CKD and peripheral arterial disease
(PAD). Symptoms of PAD may only be present in a minority
of people who have clinical evidence of PAD.579 It is there-
fore important to measure ankle-brachial index and perform
regular systematic assessment of the lower limbs of people at
high risk of PAD to identify bruits, loss of pulses, cool pale
extremities, delay in venous filling, and skin ulceration.580
4.3.1: We recommend that adults with CKD be regularly
examined for signs of peripheral arterial disease and
be considered for usual approaches to therapy. (1B)
4.3.2: We suggest that adults with CKD and diabetes are
offered regular podiatric assessment. (2A)
RATIONALE
These statements are worded in this way in order to highlight
the increased risk of PAD in people with CKD, particularly
those with CKD and diabetes.
Evidence Base
The prevalence of PAD is common in people with CKD and
it increases with lower levels of GFR (Table 31). PAD can be
Table 31 | Peripheral arterial disease and CKD
Study Population PAD definition Outcome of interest
O’Hare et al.585 NHANES age 40+ ABI o0.9 24% prevalence in people with CKD and a CrCl of
o60 ml/min (o 1 ml/s) versus 3.7% in those with
normal kidney function
O’Hare et al.587 HERS study, postmenopausal women
with known CHD
PAD event rates (amputation,
revascularization, or lumbar
sympathectomy)
Incident PAD event rates were 0.55%, 0.92%,
and 2.73% per year with CrCl 60, 30-59, and
30 ml/min/1.73 m2, respectively
O’Hare et al.586 Cardiovascular Health Study, adults
age 65+
Lower-extremity PAD procedure
(bypass surgery, angioplasty, or
amputation)
HR for PAD procedure 2.5 (95% CI 1.2-5.1) for
highest quintile of cystatin C (Z1.28 mg/l) versus
lowest (r0.9 mg/l)
De Vinuesa et al.582 102 adults in a CKD clinic, mean age
70 ± 11 years, GFR 15-60 ml/min/
1.73 m2
ABI o0.9 17% signs and symptoms of PAD, which had
passed unnoticed; 32% had ABI o0.9 (mean
0.64±0.25)
Liew et al.584 6-year follow up of 1027 subjects (ABI
index recording and GFR measured
within 90 d)
ABI o0.9 6-year mortality rate for CKD and PAD 45% versus
28% CKD alone, 26% PAD alone, and 18% for
neither condition
Wattanakit et al.588 6760 subjects, aged 45–84 years in the
Multi-Ethnic Study of Atherosclerosis
ABI o0.9 Albuminuria was associated with PAD in subjects
with diabetes (odds ratio 1.90, 95% CI 1.19–3.04)
but not in those without
Lash et al.583 3612 subjects age 58.2±11.0 years
in the Chronic Renal Insufficiency
Cohort study
ABI o0.9 Overall, 16% prevalence of PAD in subjects with
GFRo60 ml/min/1.73 m2, increasing from 4% in
those with GFR460 to 22% in those with
GFRo30 ml/min/1.73 m2
Bello et al.581 920,985 subjects with GFR and
proteinuria assessment, median
follow-up 35 months (IQR 22-44)
Time to first hospitalization with
PAD
1891 of subjects (0.2%) hospitalized at least once
for PVD, adjusted rates increased with lower GFR
Abbreviations: ABI, ankle-brachial index; CHD, coronary heart disease; CI, confidence interval; CKD, chronic kidney disease; CrCl, creatinine clearance; d, day; GFR, glomerular
filtration rate; HERS, Heart and Estrogen/Progestin Replacement Study; HR, hazard ratio; IQR, interquartile range; NHANES, National Health and Nutrition Examination Survey;
PAD, peripheral arterial disease; PVD, peripheral vascular disease.
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attributed to the greater prevalence of traditional risk factors
such as diabetes, hypertension, dyslipidemia, advanced age,
and renal-specific factors.581–588
Diabetes is the leading cause of CKD globally and the risk
of diabetic foot ulceration and lower extremity amputation in
subjects with diabetes increases dramatically with lower GFR.
In a cohort of 90,617 individuals with diabetes over a median
observation time of 2.4 years, the HR for amputation
increased from 2.08 (95% CI 1.68–2.58) for those with GFR
30-59 ml/min/1.73 m2 to 7.71 (95% CI 5.29–11.26) for those
with GFR o30 ml/min/1.73 m2 compared to reference
subjects with GFR 460 ml/min/1.73 m2.589
Screening for PAD is recommended for adults in the
general population based on age and number of risk
factors.590 Although an ankle-brachial index of o0.9 is
generally considered evidence of PAD, the utility of this
measure is unproven in CKD because of the greater
prevalence of vessel calcification. Evidence-based medical
therapies for PAD in people with CKD are similarly lacking.
Smoking cessation is mandatory. Aspirin may be beneficial
for prevention of cardiovascular events. Clopidogrel has not
been studied in people with CKD and PAD. No RCTs
evaluating percutaneous versus surgical revascularization
techniques have been conducted in people with CKD and
PAD but outcome studies all suggest that CKD confers an
increased risk of adverse outcome, regardless of the
revascularization technique employed.591,592 These state-
ments do not apply to pediatric practice.
International Relevance
There is no evidence to suggest that the international
approach to identification and management of PAD in
people with CKD should differ.
Implications for Clinical Practice and Public Policy
People with CKD are more at risk of PAD and need regular
assessment and monitoring. The role of ankle-brachial index
versus other diagnostic techniques may have implications for
future practice. Prospective data on non-surgical therapies and
data regarding percutaneous versus surgical revascularization
are required to inform policy and recommended procedure.
Areas of Controversy, Confusion, or Non-consensus
There remains ongoing debate as to the timing and use of
specific diagnostic criteria for identification of PAD in people
with CKD and no studies have examined the utility of
conventional methods in early detection of PAD in CKD. The
use of specific medical and surgical management strategies in
people with CKD and PAD has not been evaluated. There is no
reason to believe that treatment strategies should differ, though
risks of diagnostic testing (such as angiography) remain real.
4.4 MEDICATION MANAGEMENT AND PATIENT SAFETY IN CKD
Many drugs and investigative pharmaceuticals are renally
excreted and their dosage may need to be reduced in patients
with CKD in order to avoid toxicity. As many people with
CKD are elderly, there should also be consideration of
chronological age.
It is beyond the scope of this guideline to list all the
agents that may need dose adjustment in CKD or which
should be avoided due to potential nephrotoxicity. This
information is widely available in documents which may exist
at local, regional, or national bodies (e.g., British National
Formulary: www.bnf.org), and other textbooks of pharma-
cology.593,594 However key classes of commonly prescribed
drugs in people with CKD will be mentioned together with
suggestions for dose adjustment. Much of this guidance is
based upon our understanding of pharmacology and
pharmacokinetics rather than randomized control trial
evidence.
The statements presented here are intended to inform
clinicians caring for those with CKD or at risk for CKD with
respect to common clinical situations or exposures which
may put people at risk for AKI or progression of CKD.
4.4.1: We recommend that prescribers should take GFR
into account when drug dosing. (1A)
4.4.2: Where precision is required for dosing (due to
narrow therapeutic or toxic range) and/or estimates
may be unreliable (e.g., due to low muscle mass),
we recommend methods based upon cystatin C or
direct measurement of GFR. (1C)
4.4.3: We recommend temporary discontinuation of
potentially nephrotoxic and renally excreted drugs
in people with a GFR o60 ml/min/1.73 m2 (GFR
categories G3a-G5) who have serious intercurrent
illness that increases the risk of AKI. These agents
include, but are not limited to: RAAS blockers
(including ACE-Is, ARBs, aldosterone inhibitors,
direct renin inhibitors), diuretics, NSAIDs, metfor-
min, lithium, and digoxin. (1C)
4.4.4: We recommend that adults with CKD seek medical
or pharmacist advice before using over-the-counter
medicines or nutritional protein supplements. (1B)
4.4.5: We recommend not using herbal remedies in
people with CKD. (1B)
4.4.6: We recommend that metformin be continued in
people with GFRZ45 ml/min/1.73 m2 (GFR cate-
gories G1-G3a); its use should be reviewed in those
with GFR 30–44 ml/min/1.73 m2 (GFR category G3b);
and it should be discontinued in people with GFR
o30 ml/min/1.73 m2 (GFR categories G4-G5). (1C)
4.4.7: We recommend that all people taking potentially
nephrotoxic agents such as lithium and calcineurin
inhibitors should have their GFR, electrolytes and
drug levels regularly monitored. (1A)
4.4.8: People with CKD should not be denied therapies
for other conditions such as cancer but there
should be appropriate dose adjustment of cytotoxic
drugs according to knowledge of GFR. (Not
Graded)
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RATIONALE
These statements are worded in this way in order to inform
appropriate prescribing and management of medical condi-
tions in people with CKD. Recommendation 4.4.1 is
specifically worded to ensure that clinicians remember that
in those circumstances where accurate GFR is required
(narrow therapeutic or toxic window), a direct measurement,
not an estimate of GFR should be undertaken.
Evidence Base
Potential problems associated with use of medication in
people with CKD include:
a) Reduced ability to excrete drugs and/or their metabolites
b) Increased sensitivity to medications (e.g., those bound to
albumin in hypoalbuminemic states such as nephrotic
syndrome)
c) Diminished tolerance of side effects, particularly in the
elderly
d) Loss of efficacy13
Wherever possible, people with CKD should receive the
same treatment as those with normal renal function. However,
the dosages may need adjustment according to GFR.
There are medicines whose toxicity is worsened in acute
illness particularly in a setting of dehydration such as
diarrhea and vomiting. General advice about appropriate
dosing and when to restart these agents should be given to
people taking these drugs during intercurrent illness, together
with a recommendation for consultation with a health-care
professional as soon as possible.
Use of herbal and over-the-counter medicines is very
common worldwide and some (such as those containing
aristolochic acid)595,596 are known to be nephrotoxic. There is
no good quality safety or efficacy data for many of these
compounds.
Table 32 details specific advice for various classes of drugs
where CKD may be an issue. These include RAAS blocking
agents,262 beta-blockers, analgesics, antibiotics, lithium,597
hypoglycemic agents,598–600 lipid-lowering agents,449,601–604
certain chemotherapeutic agents, and anticoagulants.605
International Relevance
This guidance is based upon knowledge of pharmacology that
has universal relevance. The main international implication is
centered on costs of some newer therapies compared to the
older ones. Somewhat paradoxically, as the weight of
evidence resides mainly with agents that have been available
for longer, they have the advantage of being less costly, and
have the side effects that are well documented; thus many of
these older agents are preferred.
Pediatric Considerations
No specific recommendation for or against the use of a BSA
adjusted eGFR in relation to drug dosing can be made in
children with CKD as the majority of drug studies have been
performed in adult males and extrapolated to children
without consideration for BSA and/or pediatric renal
function or clearance.
The exception to this rule would be that for any drug
where pediatric pharmacokinetic or pharmacodynamic
studies exist, the method used in calculating the effect of
renal function should be used when estimating the need for
dose adjustments or modifications for the individual patient.
Numerous resources for dose adjustments for pediatric
CKD and ESRD patients exist, including those found in
numerous textbooks606,607 and online resources.608
An additional value of dedicated pediatric renal multi-
disciplinary teams, in terms of caring for children with CKD
and ESRD, is their ability to provide anticipatory guidance
for the patients and families. All such teams should at the
least provide written or online information to their patients
and families directing them to seek advice in situations where
they may be prescribed medications from other providers or
may be seeking over-the-counter drugs or supplements. The
presence of trained pediatric pharmacists as part of such
teams can be invaluable in achieving such support and
education for both families as well as the CKD health-care
providers and community resources such as local
pharmacists.
LIMITATIONS
People with CKD are often excluded or not identified from
trials of medications for non-renal disease. Recommenda-
tions are partly based upon knowledge of pharmacology
rather than controlled trials in carefully defined populations.
RESEARCH RECOMMENDATIONS
National and international research groups, and those
with CKD-focus organizations (International Society of
Nephrology, International Federation of Kidney Foundations,
and other national bodies) should ensure adequate repre-
sentation of people with CKD in clinical trials, leading to
an improved understanding of pharmacodynamics of those
with CKD.
4.5: IMAGING STUDIES
4.5.1: Balance the risk of acute impairment in kidney
function due to contrast agent use against the
diagnostic value and therapeutic implications of
the investigation. (Not Graded)
RATIONALE
Use of iodinated radiocontrast media has been associated
with AKI with reported rates of 0-11% depending on the
population under study, the type of agent that is used, and
the definition of nephrotoxicity.609 The following recom-
mendations are concordant with those from the American
College of Radiology (ACR),610 the European Society of
Urogenital Radiology (ESUR)611 and the KDIGO Clinical
Practice Guideine for Acute Kidney Injury.7
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Table 32 | Cautionary notes for prescribing in people with CKD
Agents Cautionary notes
1. Antihypertensives/cardiac medications
RAAS antagonists (ACE-Is,
ARBs, aldosterone antagonists,
direct renin inhibitors)
K Avoid in people with suspected functional renal artery stenosis
K Start at lower dose in people with GFR o45 ml/min/1.73 m2
K Assess GFR and measure serum potassium within 1 week of starting or following any dose escalation
K Temporarily suspend during intercurrent illness, planned IV radiocontrast administration,
bowel preparation prior to colonoscopy, or prior to major surgery
K Do not routinely discontinue in people with GFR o30 ml/min/1.73 m2 as they remain nephroprotective
Beta-blockers K Reduce dose by 50% in people with GFR o30 ml/min/1.73 m2
Digoxin K Reduce dose based on plasma concentrations
2. Analgesics
NSAIDS K Avoid in people with GFR o30 ml/min/1.73 m2
K Prolonged therapy is not recommended in people with GFR o60 ml/min/1.73 m2
K Should not be used in people taking lithium
K Avoid in people taking RAAS blocking agents
Opioids K Reduce dose when GFR o60 ml/min/1.73 m2
K Use with caution in people with GFR o15 ml/min/1.73 m2
3. Antimicrobials
Penicillin K Risk of crystalluria when GFR o15 ml/min/1.73 m2 with high doses
K Neurotoxicity with benzylpenicillin when GFR o15 ml/min/1.73 m2 with high doses (maximum 6 g/day)
Aminoglycosides K Reduce dose and/or increase dosage interval when GFR o60 ml/min/1.73 m2
K Monitor serum levels (trough and peak)
K Avoid concomitant ototoxic agents such as furosemide
Macrolides K Reduce dose by 50% when GFR o30 ml/min/1.73 m2
Fluoroquinolones K Reduce dose by 50% when GFR o15 ml/min/1.73 m2
Tetracyclines K Reduce dose when GFR o45 ml/min/1.73 m2; can exacerbate uremia
Antifungals K Avoid amphotericin unless no alternative when GFR o60 ml/min/1.73 m2
K Reduce maintenance dose of fluconazole by 50% when GFR o45 ml/min/1.73 m2
K Reduce dose of flucytosine when GFR o60 ml/min/1.73 m2
4. Hypoglycemics
Sulfonylureas K Avoid agents that are mainly renally excreted (e.g., glyburide/ glibenclamide)
K Other agents that are mainly metabolized in the liver may need reduced dose when
GFR o30 ml/min/1.73 m2 (e.g., gliclazide, gliquidone)
Insulin K Partly renally excreted and may need reduced dose when GFR o30 ml/min/1.73 m2
Metformin K Suggest avoid when GFR o30 ml/min/1.73 m2, but consider risk-benefit if GFR is stable
K Review use when GFR o45 ml/min/1.73 m2
K Probably safe when GFR X45 ml/min/1.73 m2
K Suspend in people who become acutely unwell
5. Lipid-lowering
Statins K No increase in toxicity for simvastatin dosed at 20 mg per day or simvastatin 20 mg /ezetimide
10 mg combinations per day in people with GFR o30 ml/min/1.73 m2 or on dialysis449
K Other trials of statins in people with GFR o15 ml/min/1.73 m2 or on dialysis also showed no excess toxicity
Fenofibrate K Increases SCr by approximately 0.13 mg/dl (12 mmol/l)
6. Chemotherapeutic
Cisplatin K Reduce dose when GFR o60 ml/min/1.73 m2
K Avoid when GFR o30 ml/min/1.73 m2
Melphalan K Reduce dose when GFR o60 ml/min/1.73 m2
Methotrexate K Reduce dose when GFR o60 ml/min/1.73 m2
K Avoid if possible when GFR o15 ml/min/1.73 m2
7. Anticoagulants
Low-molecular-weight heparins K Halve the dose when GFR o30 ml/min/1.73 m2
K Consider switch to conventional heparin or alternatively monitor plasma anti-factor Xa in those at high risk
for bleeding
Warfarin K Increased risk of bleeding when GFR o30 ml/min/1.73 m2
K Use lower doses and monitor closely when GFR o30 ml/min/1.73 m2
8. Miscellaneous
Lithium K Nephrotoxic and may cause renal tubular dysfunction with prolonged use even at therapeutic levels
K Monitor GFR, electrolytes, and lithium levels 6 monthly or more frequently if the dose changes
or the patient is acutely unwell
K Avoid using concomitant NSAIDs
K Maintain hydration during intercurrent illness
K Risk-benefit of drug in specific situation must be weighed
Abbreviations: ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin-receptor blocker; CKD, chronic kidney disease; GFR, glomerular filtration rate; NSAIDs, non-
steroidal anti-inflammatory drugs; RAAS, renin-angiotensin-aldosterone system; SCr, serum creatinine.
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Radiocontrast
4.5.2: We recommend that all people with GFR o60 ml/
min/1.73m2 (GFR categories G3a-G5) undergoing
elective investigation involving the intravascular
administration of iodinated radiocontrast media
should be managed according to the KDIGO
Clinical Practice Guideline for AKI including:
K Avoidance of high osmolar agents (1B);
K Use of lowest possible radiocontrast dose (Not
Graded);
K Withdrawal of potentially nephrotoxic agents
before and after the procedure (1C);
K Adequate hydration with saline before, during,
and after the procedure (1A);
K Measurement of GFR 48–96 hours after the
procedure (1C).
RATIONALE
These statements have been worded in order to inform safe
radiological investigation of people with CKD and to avoid
potential nephrotoxcity that can be associated with radi-
ological imaging.
Evidence Base
Radiocontrast media associated AKI is a largely preventable
cause of morbidity and mortality. There is no internationally
agreed definition but most studies use an increase in SCr of
40.5 mg/dl (44 mmol/l) and/or a 25% increase from baseline
SCr within 3 days of the procedure.7,609–611 Epidemiological
studies and case series have identified the following risk
factors for AKI:
a) GFRo60 ml/min/1.73 m2 (particularly ifo30 ml/min/
1.73 m2)
b) Diabetes
c) Concurrent dehydration
d) CHF
e) 470 years of age
f) Concurrent use of known nephrotoxic agents such as
NSAIDs
g) Use of high osmolality agents (especially in those with
GFR o60 ml/min/1.73 m2)
h) Use of large doses of radiocontrast media
i) Intra-arterial injection
j) Gout (hyperuricemia)
Numerous studies of preventative strategies have been
performed with the following conclusions:
a) High osmolar agents pose a greater risk of AKI in people
with CKD.609
b) Iso-osmolar agents compared to low-osmolar agents are
associated with lower rates of AKI in some but not all
studies. Wherever possible iso-osmolar agents should be
used in people with CKD at high risk for AKI (although
these tend to be more expensive).612
c) Although risk for AKI increases with GFR o60 ml/min/
1.73 m2, the rates are particularly high (7.8% in one
study) when GFR iso30 ml/min/1.73 m2. Implementing
preventative strategies for all with a GFR o60 ml/min/
1.73 m2 may not be practical but a graded risk assess-
ment taking into account all factors may be more
realistic. Some guidelines such as American College
Radiology610 and ESUR611 provide a checklist as a
means of identifying patients at risk of AKI before
investigation.
d) Extracellular volume expansion is widely recommended
although there are few good quality trials on which to
base an ideal protocol.609 0.9% saline given by contin-
uous infusion appears superior to 0.45% saline or bolus
injection and there is no demonstration of consistent
superiority of sodium bicarbonate over saline. Current
guidance suggests either infusion of 1 ml/kg body weight/
hour for 3-12 hours before and after the procedure or
100 ml/hr, beginning 6 to 12 hours before and continuing
4 to 12 hours after intravascular iodinated contrast
medium administration.609,610
e) Use of N-acetylcysteine or ascorbic acid as preventative
measures has not been shown to be a consistent benefit.
International Relevance
This guidance has universal relevance although there are cost
implications as the iso-osmolar contrast media are more
expensive.
LIMITATIONS
Some of the guidance is based upon limited evidence and
there is a need for more research into simple preventative
measure such as pre-investigation rehydration (see below).
There has not previously been a universal definition for AKI
following administration of contrast media. However,
recommendations from the KDIGO AKI Guideline suggest
that the same general AKI definition and staging be used for
changes in kidney function, irrespective of etiology.
RESEARCH RECOMMENDATIONS
Prospective studies using direct measures of GFR before and
after administration of radiological contrast media are
required to help define the incidence of AKI. Such studies
would also be able to validate creatinine or other estimates of
GFR in people undergoing radiological investigation.
Prospective controlled trials of rehydration using different
fluids (saline, bicarbonate, Hartmann’s) and validated
estimates of GFR are urgently required.
Definitive studies of N-acetylcysteine and other anti-
oxidants would help determine their usefulness or otherwise.
Gadolinium-containing contrast media
Gadolinium is a rare earth element that is naturally highly
toxic. When bound to proprietary chelating agents, it is
essentially biologically inert in people with normal renal
function and provides excellent contrast during MRI. These
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chelates are excreted unchanged by the kidneys by glomerular
filtration and have much lower direct nephrotoxicity than
conventional radioiodine contrast media.613 However over
200 cases of a scleroderma-like condition now termed
nephrogenic systemic fibrosis (NSF) following gadolinium
use in patients with CKD have been reported.613, 614
4.5.3: We recommend not using gadolinium-containing
contrast media in people with GFR o15 ml/min/
1.73 m2 (GFR category G5) unless there is no
alternative appropriate test. (1B)
4.5.4: We suggest that people with a GFR o30 ml/min/
1.73 m2 (GFR categories G4-G5) who require
gadolinium-containing contrast media are preferen-
tially offered a macrocyclic chelate preparation. (2B)
RATIONALE
These statements have been worded in order to enable safe
administration of gadolinium to people with CKD. As with
all tests requested in the CKD population, clinicians should
be aware of the risk-benefit ratio of the use of gadolinium in
people with GFR 15-29 ml/min/1.73 m2.
Evidence Base
NSF is an untreatable and sometimes fatal condition that
complicates the use of gadolinium-containing contrast media
in people with CKD. Prevention is therefore the best
approach with avoidance of gadolinium exposure unless
clinically indicated and to use the lowest risk agent at the
lowest dose.613,615
Although the risk of AKI with iodinated contrast media is
much greater than that for NSF with gadolinium, the former
is treatable with dialysis whereas the latter is not. Thus,
consideration of more conventional imaging techniques
should be undertaken in all with a GFR o30 ml/min/
1.73 m2.610,613–615
A recent meta-analysis and review have highlighted those
patients most at risk and quantified an OR for NSF of
between 20-50 for those with a GFRo15 ml/min/1.73 m2.614
While there is general agreement that patients with a GFR
415 ml/min/1.73 m2 are at increased risk, it is not possible
to derive a precise estimate. No patients with a GFR430 ml/
min/1.73 m2 have developed NSF without concomitant
liver failure.614
There is some suggestion that the type of gadolinium
preparation plays a role:614,615 Linear chelated preparations
such as gadodiamide may be more likely to cause NSF and
should be avoided when GFR is o30 ml/min/1.73 m2.
Gadoteridol, gadobutrol, or gadoterate should be considered
if MRI with contrast is clinically essential.610,613,615 Moreover,
as gadolinium is freely dialysed,616 most guidelines recom-
mend dialysis in patients with a GFR o15 ml/min/1.73 m2
or for those already on dialysis immediately after (and
perhaps repeated 24 hours later) completion of the
procedure.610,615 The role of dialysis in people with GFR
above 15 ml/min/1.73 m2 is uncertain.
International Relevance
This guidance has universal relevance although there are cost
implications as the non-linear chelated preparations are more
expensive.
Pediatric Considerations
Regarding both Recommendations 4.5.3 and 4.5.4, a number
of considerations specific to the use of gadolinium preparations
in young children and neonates must also be considered in
addition to the general admonishments against their use in
situations of GFRo30 ml/min/1.73 m2. In particular, the FDA
currently does not license any gadolinium-based contrast agent
(GBCA) product for use in children less than 2 years of age; and
likewise the European Medicines Agency cautions against the
use of any GBCA in a child less than 1 year of age.
In addition, the ability to accurately estimate the relative
value of a neonate or young infant’s GFR leads to great
difficulty in terms of assigning risk of GBCA exposure if one
bases this on renal clearance. In a recent paper by Meng and
colleagues,617 they surveyed a worldwide group of both
cardiologists and radiologists with respect to their use of
gadolinium in their pediatric MRI practice. While 93% of the
respondents did evaluate renal function in some or all of
their patients, only a slight majority (54%) used an
estimating formula, most often the Schwartz equation, with
the remainder relying on SCr alone (31%) or urine output
(6%). Perhaps of most concern was that renal function was
assessed in only 33% and 31%, respectively, of patients
classified as ‘all neonates’ or ‘all patients o1 week of age.’
Equally concerning was the fact that 13% of the respondents
would give gadolinium to some of these children in the face
of a GFR o30 ml/min/1.73 m2.
In recognition of our inability to accurately measure GFR
in the neonate and, by extension, the clearance of compounds
such as gadolinium, all nephrologists and radiologists must
exercise caution in terms of use of GBCA in this potentially
high-risk population, and all other imaging modalities
should be considered prior to choosing one requiring
gadolinium exposure.
LIMITATIONS
The evidence is largely based upon case series rather than
prospective studies or RCTs.
RESEARCH RECOMMENDATIONS
As for iodinated contrast media, a prospective study of people
with CKD undergoing nuclear MRI with gadolinium contrast
would help define change in GFR and validate estimators.
Because NSF is such a serious condition, an RCT of dialysis in
people with GFR o30 ml/min/1.73 m2 would help to
determine risk-benefit in these patients, though recruitment
may be difficult due to potential ethical concerns.
Bowel preparation
The increasing use of colonoscopy as a screening tool for
bowel cancer has resulted in many people undergoing bowel
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preparation with oral sodium phosphate-containing prepara-
tions. Case reports of acute and late irreversible renal failure
with biopsy-proven phosphate deposition have led to a new
disease entity termed acute phosphate nephropathy.618,619
Less than 40 definite cases have been reported and these have
been extensively reviewed.
4.5.5: We recommend not to use oral phosphate-contain-
ing bowel preparations in people with a GFR o60
ml/min/1.73 m2 (GFR categories G3a-G5) or in
those known to be at risk of phosphate nephropathy.
(1A)
RATIONALE
This statement has been worded in order to enable safe bowel
preparation in people with CKD who need to undergo
investigation of bowel disease.
Evidence Base
Electrolyte disturbances that are sometimes severe and
include hyperphosphatemia, hypocalcemia, hypo- and
hypernatremia, and hypokalemia have been reported in
normal volunteers undergoing oral phosphate bowel prepa-
ration.620 Renal injury has been reported in a small number
of people although the condition is likely to be under-
recorded. A recent study from Iceland estimated the
incidence to be around 1 per thousand doses621 but others
would suggest incidence rates of between 1% and 4%.618,619
Two broad patterns of renal injury have been des-
cribed. An early symptomatic response associated with severe
hyperphosphatemia and hypocalcemia and a later (days to
months) irreversible kidney injury associated with a specific
tubulointerstitial calcium phosphate deposition.618,619
The following people are said to be at particular risk
although the link to kidney injury is associative in many cases
and firm evidence is lacking:
a) GFR o60 ml/min/1.73 m2
b) 460 years of age
c) Female
d) Hypertension
e) Diabetes
f) CHF
g) Dehydration
h) Active colitis
i) Concurrent use of RAAS blocking agents, diuretics,
lithium, NSAIDs
j) Large and/or repeat dosing of oral phosphate prepara-
tions
k) Hypoparathyroidism
Although the FDA has banned oral phosphate solutions,
there is no qualitative difference with tablet preparations.
Both should be avoided in people at risk and this is the
current recommendation of the American Society for
Gastrointestinal Endoscopy.622
There is some debate as to whether the cause of the kidney
injury is entirely due to dehydration rather than phosphate
use per se.623 However, it is hard to understand why calcium
phosphate deposits occur and cause late renal impairment if
dehydration was the only factor.
There is a single RCT of phosphate versus non-phosphate
preparations but assessment of renal function was limited to
change in SCr and GFR at baseline is not reported.624
Notwithstanding these limitations, there were greater changes
in serum potassium, calcium, and phosphate in those given
sodium phosphate-containing preparations.
As there are non-phosphate-containing bowel prepara-
tions available, these should be used in all the above groups
(and arguably in all people given the biochemical abnorm-
alities observed in normal volunteers). As for radiocontrast
media, rehydration with saline may be required in the frail
and ill irrespective of the bowel preparation that is used.
International Relevance
This guidance has universal relevance but non-phosphate-
containing bowel preparations are more expensive, so the use
of these agents may differ around the world.
LIMITATIONS
The data are based upon case series with a limited number of
affected individuals and retrospective population studies.
RESEARCH RECOMMENDATIONS
Prospective study in people with normal renal function and
those with different severities of CKD are urgently required
in order to define the acute biochemical and metabolic effects
of phosphate-containing bowel preparations. There is also a
need for a study of all people undergoing bowel preparation
with whatever preparation in order to explore the effects on
GFR on the incidence of this complication. More definitive
exploration of rehydration therapy (type and volume) in
people with CKD undergoing bowel preparation is urgently
needed.
4.6 CKD AND RISKS FOR INFECTIONS, AKI,
HOSPITALIZATIONS, AND MORTALITY
The following section gives guidance for the care of people
with CKD given that they are at increased risk for a number
of events such as infections, AKI, CVD, hospitalizations, and
mortality. Appreciating that increased risk and implementing
some of the recommendations below may result in improved
outcomes for people. It will be important to develop policies
and robust research agendas to address areas which do not
have a substantial evidentiary base.
CKD and risk of infections
CKD is associated with significant major infectious compli-
cations, which occur at rates 3 to 4 times the general
population. Infection is an important cause of morbidity and
mortality among patients with kidney failure and is the
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second leading cause of death following CVD. CKD may be a
risk-multiplier for acute infectious disease-associated mor-
tality, as it is for CVD. Despite a less effective response to
vaccination, there are data suggesting benefit from immuni-
zation among people with CKD as in the general population.
4.6.1: We recommend that all adults with CKD are
offered annual vaccination with influenza vaccine,
unless contraindicated. (1B)
4.6.2: We recommend that all adults with eGFR o30 ml/
min/1.73 m2 (GFR categories G4-G5) and those at
high risk of pneumococcal infection (e.g., nephrotic
syndrome, diabetes, or those receiving immuno-
suppression) receive vaccination with polyvalent
pneumococcal vaccine unless contraindicated. (1B)
4.6.3: We recommend that all adults with CKD who have
received pneumococcal vaccination are offered
revaccination within 5 years. (1B)
4.6.4: We recommend that all adults who are at high risk
of progression of CKD and have GFRo30 ml/min/
1.73 m2 (GFR categories G4-G5) be immunized
against hepatitis B and the response confirmed by
appropriate serological testing. (1B)
4.6.5: Consideration of live vaccine should include an
appreciation of the patient’s immune status and
should be in line with recommendations from
official or governmental bodies. (Not Graded)
4.6.6: Pediatric immunization schedules should be followed
according to official international and regional
recommedations for children with CKD. (Not Graded)
RATIONALE
CKD is associated with alterations in primary host defense
mechanisms and increases the risk of bacterial infections
(Table 33). Epidemiological study suggests that the 3 most
commonly seen infectious complications in the CKD
population are: urinary tract infection, pneumonia, and
sepsis. In the general population, there is strong evidence that
preventive measures are effective in adults and there are data
suggesting benefit from immunization in people with CKD.
Evidence Base
Previous investigations have firmly established ESRD as a
strong risk factor for infectious complications.625–628 How-
ever, few epidemiologic reports have addressed the risk of
infections in people with CKD not treated with dialysis.629,630
Data from the US Renal Data System (USRDS) suggest that
higher rates of hospital admission because of septicemia are
noted in people with CKD compared with those without
CKD.631 Comprehensive studies of the absolute rates, risk
factors, clinical course, and outcomes of different types of
clinically relevant infections across the spectrum of CKD are
not available.
Among people with CKD, very few studies have examined
the incidence or prevalence of infections and no published
data describe GFR category–specific infection rates. Among
Medicare beneficiaries aged more than 66 yr, people with
diagnosed CKD seem to have substantially higher rates of
hospitalization for diagnoses of pneumonia and sepsis
compared with people without diagnosed CKD.628 In
addition to an increased incidence of being hospitalized
with infections, people with CKD have longer lengths of
hospital stay during infection-related admissions compared
with people without CKD.632
Among USRDS data admission rates for all causes, CVD
and infection, are 38–46% higher for those with CKD than
for those without.633 Rates for pneumonia in CKD were
nearly three times higher than those for non-CKD.
Hospitalizations for bacteremia/septicemia, were nearly four
times higher for people with CKD compared to those
without. Hospitalization rates for urinary tract infections
were three-fold higher for people with CKD.
In people with ESRD, the function of polymorphonuclear
white blood cells, lymphocytes, and monocytes is altered,
resulting in an impaired host response to infection.636–638
However, these issues have not been adequately investigated
in people with CKD.
There is a growing body of evidence in the general
population for reduction in infections, hospitalizations, and
mortality as a result of immunizations. Current data suggest
that vaccination is an underused prevention strategy in the
CKD and ESRD populations.639 Potential barriers to
immunization that are specific to the CKD populations have
not been systematically examined. Although lower vaccine
responsiveness has been widely recognized in the ESRD
population, to what extent moderate to advanced CKD
modifies vaccine responsiveness remains unclear.640–642
Studies that have examined vaccination in the setting of
CKD or ESRD have been limited by small study size, variable
follow-up, and ascertainment of surrogates for vaccine
effectiveness such as antibody response and rate of antibody
decline after vaccination as opposed to vaccine efficacy for
preventing infection.643
Influenza A and B vaccine. Despite potentially impaired
antibody responses, a 2-year analysis of US Medicare claims
data found that people vaccinated against influenza A and B
on dialysis had a substantially lower chance of any-cause
hospital admission and any-cause death than those patients
not vaccinated on dialysis.644 This finding might indicate
clinical effectiveness of vaccinating this population but its
observational design might also reflect differences in the
underlying clinical status among people vaccinated and not
Table 33 | Risk factors for infection in people with CKD
Advanced age
High burden of coexisting illnesses such as diabetes
Hypoalbuminemia625
Immunosuppressive therapy628
Nephrotic syndrome634
Uremia
Anemia and malnutrition635
High prevalence of functional disabilities
Abbreviation: CKD, chronic kidney disese
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vaccinated. No unique adverse events related to influenza
vaccine have been identified in people on dialysis.
Pneumococcal vaccine. People with kidney disease
vaccinated with the pneumococcal vaccine seem to
develop different serotype-specific titers, develop lower levels
of antibody titers, and have a more rapid loss of antibody
titers as compared with healthy control subjects.639,645,646
Practitioners should be aware of the impact of
specific vaccines on responsiveness and duration of respon-
siveness. Revaccination practices will be dictated by that
knowledge.
Hepatitis B vaccine. Widespread hepatitis B virus (HBV)
vaccination at the onset of dialysis has led to a marked
reduction of HBV infections in people with ESRD,
although improved screening of blood products and
dissemination of recommendations for reducing the spread
of HBV infections in dialysis units have also likely
contributed.647 Among people with moderate to advanced
CKD, hepatitis B vaccination responsiveness has been shown
to range from approximately 60 to 80% depending on the
dosage, number of administered vaccines, and study
population. Although findings have been inconsistent as to
whether the level of GFR affects vaccine responsiveness in
people with CKD640,642 those with higher GFR are more
likely to respond with seroconversion, independent of other
factors.640
S. aureus vaccine. StaphVAX has not been shown to be
efficacious in reducing the risk for Staphylococcus aureus
bacteremia in people on hemodialysis.648,649 No data are
published in people with CKD.
Live vaccines. Due to the fact that people with CKD are
often immunocompromised, live vaccines should only be
used with caution on an individual basis.
In summary, although some vaccines (like influenza) in
usual doses provide protection, other vaccines (HBV and
pneumococcal) require more frequent dosing or larger doses
to achieve and maintain protective antibody titers. Frequency
and type of vaccination will vary according to local
circumstances and prevalence of disease.
International Relevance
The availability of different vaccinations may vary worldwide,
as does the prevalence of specific bacterial, viral, and other
infections. It is reasonable to offer individuals appropriate
immunization according to local practices.
Implications for Clinical Practice and Public Policy
Vaccines for influenza, hepatitis B, and pneumococcus are
currently recommended for people with CKD by the local,
regional, or national advisory committees on immunization
practices from most countries.
Current recommendations are to:
K Provide influenza vaccination annually to people with
CKD.
K Provide pneumococcal vaccine with a single booster dose
5 years after the initial dose.
K Provide HBV vaccine to people with CKD who are likely
to require RRT. Although the recommendation is to give
the HBV vaccine during more severe CKD (GFRo15 ml/
min/1.73 m2), it may be preferable to give this earlier to
maximize the chances of achieving immunity; there are
data to support this practice.640 This would also ensure
that all patients are immunized against HBV before
receiving a transplant. As protective antibody levels may
fall, this should be checked (possibly annually) with
booster doses given if appropriate.
Areas of Controversy, Confusion, or Non-consensus
Much remains to be understood concerning impaired host
response to infection in patients with CKD.
K Studies should be undertaken to determine the absolute
rates, risk factors, and clinical course of different types of
clinically relevant infections across the spectrum of CKD,
by GFR and albuminuria category, and by cause.
K The outcomes across the range of acute infections in
CKD population need to be ascertained.
K Studies should be undertaken to assess the rate of decline
of antibody titers post-vaccination and the efficacy of
immunization in people with CKD.
Pediatric Considerations
Current immunization schedules for children are regularly
updated by both the US Centers for Disease Control and
Prevention650 and American Academy of Pediatrics.651
Current and comprehensive immunization recommendations
for children with CKD have been published by Neu in 2012.652
The paper addresses key issues regarding the use of vaccines
in CKD pediatric populations who are receiving concomitant
immunosuppression and in those awaiting transplantation.
The need for, and interpretation of, protective antibody levels
for those vaccines where this is indicated is described.
An oversimplified summary of the recommendations
would be to provide all recommended childhood vaccines
to every child with CKD with the exception of any live viral
vaccine in a child receiving immunosuppressive medications.
Likewise children on dialysis should not receive the live
attenuated influenza vaccine although the inactivated version
can and should be given to all children with CKD on an
annual basis otherwise. Pneumococcal vaccination is parti-
cularly important in children with nephrotic syndrome and
those with CKD, and current vaccination schedules and
products should be carefully reviewed to ensure proper
serotype coverage is being provided. Hepatitis B status and
vaccination are of extreme importance in all children who
may go onto dialysis – and specific recommendations for
ongoing monitoring and interpretation of antibody levels
should be carefully reviewed.
CKD and risk of AKI
Due to the epidemiological association between CKD and
AKI and the number of observational studies reporting an
association between pre-existing CKD and AKI, CKD is
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considered the most consistent pre-existing condition
associated with a high risk of AKI. However the potential
linkage between patients with AKI, CKD, and ESRD has been
inadequately studied to date and remains ill defined. This
section describes AKI as a complication which needs to be
managed in those with CKD. Given its association with
progression, it is also described in that section.
4.6.7: We recommend that all people with CKD are
considered to be at increased risk of AKI. (1A)
4.6.7.1: In people with CKD, the recommendations
detailed in the KDIGO AKI Guideline should
be followed for management of those at risk
of AKI during intercurrent illness, or when
undergoing investigation and procedures that
are likely to increase the risk of AKI. (Not
Graded)
RATIONALE
Observational data suggest a strong association between pre-
existing CKD and AKI. The appreciation that CKD patients
may be more susceptible to AKI is the purpose of the above set
of statements. However, methodological issues such as how
CKD and AKI are defined in clinical studies and the statistical
adjustments for non-uniformity of comorbidities among
various studies may affect the validity of observed associations.
Evidence Base
CKD is designated as a risk factor for AKI because of
the epidemiological association between the two.263,264 A
number of studies in a variety of settings report an associ-
ation between pre-existing CKD and AKI. 265-271 CKD is a
potent predictor of acute decline in kidney function
following exposure to radiocontrast,272 major surgery,273
and other medical conditions.274
Hsu et al.14 compared the pre-hospitalization MDRD GFR
of 1764 adult members of the Kaiser Permanente Northern
California health-care system who developed dialysis-requir-
ing AKI during hospitalization with 600,820 individuals who
did not. Compared with a reference baseline GFR ofZ60 ml/
min/1.73 m2, a baseline GFR of 45–59 ml/min/1.73 m2 was
associated with an adjusted OR of in-hospital AKI of 1.66
(95% CI 1.40–1.97). For GFR values of 15–29 ml/min/1.73 m2,
the adjusted OR for in-hospital AKI was 20.42 (95% CI
17.40–23.96). The presence of diabetes, hypertension, and
proteinuria increased the likelihood of developing in-hospital
AKI, with adjusted ORs of 1.99 (95% CI 1.78–2.23), 1.55
(95% CI 1.37–1.76) and 2.84 (95% CI 2.52–3.19), respectively.
The authors concluded that CKD is the main risk factor for
AKI during hospitalization. A contrasting approach by Singh
et al. defined AKI as dialysis-requiring acute renal failure.275
Because the clinical decision to dialyze a patient is frequently
influenced by a higher overall SCr, presence of hemodialysis
access, or consideration of inevitable progression to ESRD,
this definition of AKI could bias toward capturing more AKI
cases in CKD patients. Moreover, in patients with advanced
CKD, the progression of CKD to ESRD may sometimes be
difficult to separate from acute-on-chronic renal failure. A
cohort study by Lafrance et al. followed a referred CKD
population in British Columbia for a median of 19.4 months
after achieving a GFR of r30 ml/min/1.73 m2. Forty-five
percent had at least one episode of AKI.276 In another cohort
study of 920,985 adults in Alberta, Canada with at least one
outpatient measurement of SCr and proteinuria and not
requiring chronic dialysis, risk of admission with AKI
increased with heavier proteinuria and reduced GFR.16
International Relevance
These guidelines about AKI have relevance around the world.
While the causes of AKI may differ by region, country, socio-
economic status, and age, the consequences remain the
similar. Where there are no facilitities to support AKI or
CKD, people will die.
Areas of Controversy, Confusion, or Non-consensus
Interpretation of published data examining the influence of
pre-existing CKD on the increased likelihood of AKI is
potentially confounded by a number of issues. These include
the comorbidities associated with CKD, influenced by
repeated exposure to various nephrotoxic insults or in-
hospital errors,57,277 or primarily due to the altered
physiology in CKD. There are also methodological issues
such as how CKD and AKI are defined in clinical studies and
the varying statistical adjustments for comorbidities which
may affect the validity of observed associations.
A further important issue to clarify is whether pre-existing
CKD influences the outcome of AKI. Currently, there is no
single biomarker that can differentiate ‘acute’ from ‘chronic’
kidney disease and help to address this issue. Several large
observational and database studies report, surprisingly, lower
in-hospital mortality in patients with AKI superimposed on
CKD compared with controls.278-283 Data from PICARD
reveal lower in-patient mortality and median length of stay in
ICU subjects with acute-on-chronic renal injury compared
with non-CKD subjects with AKI, though the post-discharge
dialysis rates were higher in subjects with pre-existing CKD.284
Pediatric Considerations
The relative paucity of pediatric specific guidelines (due to
lack of high-quality studies) in the KDIGO AKI guideline
would suggest that the use of pediatric data and review
papers as well as relevant pediatric nephrology texts would be
of benefit to the practitioner interested in reviewing this topic
in greater detail and applying pediatric data to their
practice.653–658
RESEARCH RECOMMENDATIONS
Prospectively designed clinical studies with a clear and
uniform definition of CKD and AKI and adjusted for
comorbidities are needed to determine:
K the frequency of AKI events in a CKD population
K the outcome of AKI in patients with CKD condition
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K the importance of proteinuria in addition to low GFR in
the risk of AKI
CKD and risk of hospitalization and mortality
Regardless of the method used to estimate GFR, hospitaliza-
tion and mortality rates are higher in people with CKD. Exact
rates vary with comorbidity and severity of CKD, and are not
well-defined. Selection of interventions that could reduce
hospitalizations, morbidity, mortality, and costs in people
with CKD is not well-studied.
4.6.8: CKD disease management programs should be
developed in order to optimize the community
management of people with CKD and reduce the
risk of hospital admission. (Not Graded)
4.6.9: Interventions to reduce hospitalization and mor-
tality for people with CKD should pay close atten-
tion to the management of associated comorbid
conditions and cardiovascular disease in particular.
(Not Graded)
RATIONALE
There are observational and database studies reporting an
association between pre-existing CKD and hospitalizations
and mortality. A better understanding of the rates, causes,
and risk factors for hospitalization among people with CKD
would allow estimates of the economic burden of CKD and
identification of those at risk for increased resource
utilization. People with CKD are an ideal target for
interventions aimed at reduction of morbidity, hospitaliza-
tion, mortality, and costs. These statements suggest that a
coordinated approach to the identification and management
would result in better outcomes and are intended as ‘best
practices’ statements, recognizing the difficulty in developing
an evidence base while addressing issues related to resource
allocations (Table 34).
Evidence Base
Mortality rates remain high (16-22%) with the use of
dialysis, with more than half of all deaths related to
CVD. Less is known about mortality and CVD rates, and
resource use among persons with a reduced GFR who are
not yet receiving maintenance dialysis. Few studies have
investigated the association between CKD and the risk of
hospitalization.
Data from the USRDS reveal that hospitalization rates
vary with comorbidity and interact with degrees of CKD.
Adjusted rates are 38% higher in people with CKD and 19%
greater in people with CKD and GFR under 60 ml/min/
1.73 m2 than in those with GFR 460 ml/min/1.73 m2, who
in turn are 20% higher than in people without CKD-
illustrating the graded impact of advancing kidney disease.
Not surprisingly, rates of cardiovascular hospitalization are
greater for people with CKD, particularly those with
increasing severity of CKD.659 In both the CKD and non-
CKD populations, adjusted rates of hospitalization increase
with greater comorbidity. In 2008, for example, the rate for
people with CKD with both diabetes and CHF was 726 per
1000 person-years at risk — 85% greater than the rate of 393
among people with neither diagnosis. Rates of admission for
CVD increase even more in the higher categories of GFR.
Among Medicare subjects, the rate of 141 admissions per 1000
person-years for those with GFRo60 ml/min/1.73 m2 is 26%
higher than the rate of 112 reported for those with CKD and
GFRZ60 ml/min/1.73 m2. The admission rates of 101 and 90
reported for MarketScan and Ingenix i3 subjects with GFR
o60 ml/min/1.73 m2 are 48 and 16% greater, respectively,
than those occurring in people with higher GFRs.633 Adjusted
rates of mortality in USRDS 2008 increased with age, and
were highest in people with advanced categories of GFR:
31–72% higher, for example, in people with GFR o60 ml/
min/1.73 m2 compared to those with no CKD. By gender,
rates in men with CKD were 91.8 per 1000 person-years at
risk compared to 85.6 in women. Rates for people with CKD
overall were similar in whites and African Americans, but in
people with GFR o60 ml/min/1.73 m2, rates for African
Americans were 18% higher than those for whites, at 95.0 and
80.5 per 1000 person-years, respectively.633
Khan et al.660 confirmed that hospital utilization among
people with CKD is high. During a median follow-up of 11.4
months, 47% of subjects had at least one hospitalization and
there were on average 0.96 hospitalizations, 6.6 hospital days,
and 4.0 outpatient nephrology visits per person-year at risk.
Cardiac disease/hypertension was the most common primary
diagnosis of hospitalizations and progression of CKD/acute
kidney failure was the most common secondary cause of
hospitalization. The authors had previously shown that the
dialysis population at their institution had 2.2 hospitaliza-
tions and 14.8 hospital days per person-year at risk,659 which
was similar to that among US hemodialysis patients between
1996 and 1998, who had 1.9 hospitalizations and 14 hospital
days per person-year at risk.661 In the general population,
there were 0.31 hospitalizations and 1.9 hospital days per
person in 1998.662
Go et al.58 reported an independent, graded association
between GFR and the risk of death, cardiovascular events,
and hospitalization in 1,120,295 adults within a large,
integrated system of health-care delivery in whom SCr had
been measured between 1996 and 2000 and who had not
Table 34 | Components of community CKD management
programs
Disease monitoring
Integration with other chronic disease management programs including
diabetes, hypertension and heart failure
Medication management and dietary advice
Anemia management programs
Vaccination programs
Information and psychosocial support
Renal replacement therapy (dialysis and transplant) education
Advanced care planning and end-of-life care (where appropriate)
Abbreviation: CKD, chronic kidney disease.
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undergone dialysis or kidney transplantation. These risks
were evident at GFR o60 ml/min/1.73 m2 and substantially
increased at GFR o45 ml/min/1.73 m2.
The higher hospital utilization among people with CKD
compared to the general population, and the similarity in the
comorbid conditions and the causes of hospitalization
between people with CKD and ESRD, confirm the hypothesis
that the complications and comorbidity observed in ESRD
are manifest earlier in the disease process. Previous studies
have demonstrated an association between age, gender, race,
cardiac disease, peripheral vascular disease, serum albumin
and hematocrit levels, and resource utilization among people
on dialysis.659,663,664 Holland et al.665 identified baseline
predictors of first non-elective hospitalization among a
retrospective cohort of 362 predialysis subjects. Multivariate
analysis, adjusted for baseline creatinine concentration,
selected advanced age (RR 1.02; 95% CI 1.01–1.03), angina
(RR 1.9; CI 1.37–2.61), peripheral vascular disease (RR 1.55,
CI 1.05–2.27), and Hb concentration (RR 0.99, CI 0.94–0.98)
as independent predictors of hospitalization. These
comorbid conditions progressively worsen with advancing
kidney disease and result in a substantial proportion of
people having severe complications by the time they come
to RRT.
Interventions to reduce hospitalizations and mortality for
people with CKD should pay close attention to the manage-
ment of associated comorbid conditions and CVD.666 Closer
attention to the management of heart disease in this
population could substantially improve outcomes.667
The influence of correction of anemia on hospitalization is
controversial. Dru¨eke et al.668 randomly assigned 603 subjects
with GFR 15-35 ml/min/1.73 m2 and mild-to-moderate
anemia (Hb level: 11.0-12.5 g/dl [110-125 g/l]) to a target Hb
value in the normal range (13.0-15.0 g/dl [130-150 g/l]) or
the subnormal range (10.5-11.5 g/dl [105-115 g/l]). There
were no significant differences between the two groups in the
incidence of hospital admission (61% and 59%, respectively)
or mean duration of hospitalization for cardiovascular
reasons (33.0 and 28.2 days, respectively). Singh et al.669
studied 1432 people with CKD, 715 of whom were randomly
assigned to receive a dose of epoetin alfa targeted to achieve
a Hb level of 13.5 g/dl (135 g/l) and 717 of whom
were assigned to receive a dose targeted to achieve a level
of 11.3 g/dl (113 g/l). The median study duration was
16 months. The primary end point was a composite of death,
MI, hospitalization for CHF (without RRT), and stroke. They
observed an increased risk of the primary composite end
point in the high Hb group as compared with the low Hb
group. Death and hospitalization for CHF accounted for
74.8% of the composite events. The Trial to Reduce
Cardiovascular Events with Aranesp Therapy (TREAT)375
study involved 4038 people with diabetes, CKD, and anemia.
Subjects were randomly assigned to treatment with darbe-
poetin alfa to achieve a Hb level of approximately 13 g/dl
(130 g/l) or to placebo, with rescue darbepoetin alfa when the
Hb level was less than 9.0 g/dl (90 g/l). The primary end
points were the composite outcomes of death or a
cardiovascular event (nonfatal MI, CHF, stroke, or hospita-
lization for myocardial ischemia) and of death or ESRD.
Again there were no significant between-group differences in
the outcomes of interest.
International Relevance
It is of benefit for all jurisdictions to appreciate the increase
in resource utilization by CKD populations. Identification
of people at risk for increased resource utilization and
economic burden of CKD should result in strategies to
attenuate that risk or address the resource implications.
Selection of interventions that could reduce hospitalizations,
morbidity, mortality, and costs in these populations should
be evaluated.
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